This activity is supported by independent medical education grants from 4D Molecular Therapeutics; Alkeus Pharmaceuticals, Inc.; Genentech, a member of the Roche Group; Neurotech Pharmaceuticals ...

This guide covers all the logo design rules, best practices, tips, examples, and more to equip you with the knowledge for crafting brilliant logos. Logos are one of the most vital elements of any ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other best pharma stocks to buy according to hedge funds. The US pharmaceutical sector is ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Earlier this week, AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research ...

The latest price target for AbbVie (NYSE:ABBV) was reported by Wells Fargo on March 5, 2025. The analyst firm set a price target for $240.00 expecting ABBV to rise to within 12 months (a possible ...

The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox). Financial Milestones: AbbVie's Journey Market Capitalization Analysis: With an elevated ...

AbbVie was downgraded to "Hold" due to high debt, fluctuating earnings, and declining Humira sales, but the stock outperformed with a 31% return since July 2024. Despite mixed quarterly results ...

AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the ...

AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra. AbbVie said it will pay up to about $2.2 billion for the drug GUBamy, which is currently in a Phase 1 ...

NORTH CHICAGO, IL, USA and HØRSHOLM, Denmark I March 3, 2025 I AbbVie (NYSE: ABBV) and Gubra A/S (CPSE:GUBRA), a company specializing in preclinical contract research services and peptide-based drug ...